Rani Therapeutics Holdings, Inc.
RANI
$0.6244
$0.075813.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -83.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -83.27% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -83.27% | |||
| SG&A Expenses | -10.95% | 2.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.79% | -0.71% | |||
| Operating Income | 12.55% | -6.84% | |||
| Income Before Tax | 11.89% | 18.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.89% | 18.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -17.21% | -19.20% | |||
| Net Income | 7.87% | 18.81% | |||
| EBIT | 12.55% | -6.84% | |||
| EBITDA | 12.73% | -7.14% | |||
| EPS Basic | 15.70% | 20.70% | |||
| Normalized Basic EPS | 8.74% | -232.14% | |||
| EPS Diluted | 15.70% | 20.70% | |||
| Normalized Diluted EPS | 8.74% | -232.14% | |||
| Average Basic Shares Outstanding | 9.28% | 2.39% | |||
| Average Diluted Shares Outstanding | 9.28% | 2.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||